Tayyaba Ikram Qazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tayyaba Ikram Qazi has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Bilal Wazir Khan
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
5 shared publications - Aleena Amir Malik
Department of Medicine, United Medical and Dental College, Karachi, Pakistan
4 shared publications - Muhammad Huzaifa Khattak
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
4 shared publications - Asia Batool
Department of Medicine, Sir Syed College of Medical Sciences, Karachi, Pakistan
3 shared publications - Muhammad Yahya
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
3 shared publications - Atiqullah Sadaqat
Department of Curative Medicine, Faculty of Medicine, Kateb University, Kabul, Afghanistan
2 shared publications
Latest Publications
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer
Objectives: Sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to evaluate the effectiveness and safety of SG using only randomized controlled trials (RCTs). Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, Scopus, and Cochrane Library were searched from June 2025 to April 2026. RCTs comparing SG with standard therapies in breast cancer patients were included. Outcomes included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events. Random-effects models were used to calculate pooled risk ratios (RR) and hazard ratios (HR) with 95% CIs. Risk of bias (RoB 2) and GRADE approaches were applied. Results: Six RCTs (n=2508) were included. SG significantly improved ORR (RR=1.62; 95% CI: 1.11-2.37), OS (HR=0.68; 95% CI: 0.54-0.86), and PFS (HR=0.60; 95% CI: 0.51-0.72), although heterogeneity was moderate to high in some analyses. SG was associated with a higher risk of grade ≥3 adverse events (RR=1.12; 95% CI: 1.05-1.20), particularly diarrhea and neutropenia. Subgroup and sensitivity analyses confirmed the robustness of efficacy outcomes. Conclusions: SG provides significant improvements in survival and response outcomes in advanced breast cancer, with a manageable toxicity profile. These findings support its role as an effective treatment option, particularly in pretreated patients, while highlighting the need for further research to optimize its clinical use.
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer
Objectives: Sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to evaluate the effectiveness and safety of SG using only randomized controlled trials (RCTs). Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, Scopus, and Cochrane Library were searched from June 2025 to April 2026. RCTs comparing SG with standard therapies in breast cancer patients were included. Outcomes included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events. Random-effects models were used to calculate pooled risk ratios (RR) and hazard ratios (HR) with 95% CIs. Risk of bias (RoB 2) and GRADE approaches were applied. Results: Six RCTs (n=2508) were included. SG significantly improved ORR (RR=1.62; 95% CI: 1.11-2.37), OS (HR=0.68; 95% CI: 0.54-0.86), and PFS (HR=0.60; 95% CI: 0.51-0.72), although heterogeneity was moderate to high in some analyses. SG was associated with a higher risk of grade ≥3 adverse events (RR=1.12; 95% CI: 1.05-1.20), particularly diarrhea and neutropenia. Subgroup and sensitivity analyses confirmed the robustness of efficacy outcomes. Conclusions: SG provides significant improvements in survival and response outcomes in advanced breast cancer, with a manageable toxicity profile. These findings support its role as an effective treatment option, particularly in pretreated patients, while highlighting the need for further research to optimize its clinical use.
- Open Access
- 21 July 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Endoscopic versus open radial artery harvesting for coronary artery bypass grafting: an updated systematic review, meta-analysis, and GRADE assessment
Endoscopic radial artery harvesting (ERAH) is a minimally invasive alternative to open radial artery harvesting (ORAH) for coronary artery bypass grafting
- 21 July 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessEndoscopic versus open radial artery harvesting for coronary artery bypass grafting: an updated systematic review, meta-analysis, and GRADE assessment
Endoscopic radial artery harvesting (ERAH) is a minimally invasive alternative to open radial artery harvesting (ORAH) for coronary artery bypass grafting
- Open Access
- 23 June 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 124
Comparing fractional CO₂ laser and needling-based modalities in facial acne scar treatment: a comprehensive systematic review and meta-analysis
Facial acne scarring is a widely prevalent dermatological disease manifested as a permanent aftereffect of acne vulgaris. While fractional CO₂ laser and needling procedures are essential to treating atrophic acne scars, comparative and safety data remains limited. This systematic review and meta-analysis directly compares their efficacy and safety. According to PRISMA guidelines, PubMed, Cochrane, Google Scholar, and ClinicalTrials.gov were systematically searched. Only studies comparing fractional CO₂ laser with needling-based monotherapy treating facial atrophic acne scars in adults were included. A random-effects model was employed for meta-analysis using Review Manager (RevMan) to compare efficacy and safety outcomes. A total of 17 studies were included in the meta-analysis. For primary efficacy outcomes, the results were non-significant for mean scar score reduction (SMD: -1.08, 95% CI: [-2.48, 0.32], I² = 97%) or mean quantitative scar reduction (SMD: 0.12, 95% CI: [-0.80, 1.04], I² = 92%), with significant heterogeneity. However, categorical treatment success was significantly high for CO₂ laser (RR: 1.10, 95% CI: [1.01, 1.20], I² = 0%). For safety outcomes, fractional CO₂ laser showed significantly high risk of post-inflammatory hyperpigmentation (PIH) as compared to standard microneedling (RR: 3.04, 95% CI: [1.49, 6.21], I² = 3%), but showed significantly low pain scores as compared to RF microneedling (SMD: -0.74, 95% CI: [-1.27, -0.21], I² = 0%). No significant differences were found for erythema, crusting/scabbing, or edema. Both fractional CO₂ laser and microneedling procedures show comparable efficacy in treating atrophic acne scars, however, patient variables such as skin type, scar type, and possible complications should be taken into consideration. Moreover, further tailored therapies are crucial to treating acne scars with low risk for complications.
- 23 June 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 124
Open AccessComparing fractional CO₂ laser and needling-based modalities in facial acne scar treatment: a comprehensive systematic review and meta-analysis
Facial acne scarring is a widely prevalent dermatological disease manifested as a permanent aftereffect of acne vulgaris. While fractional CO₂ laser and needling procedures are essential to treating atrophic acne scars, comparative and safety data remains limited. This systematic review and meta-analysis directly compares their efficacy and safety. According to PRISMA guidelines, PubMed, Cochrane, Google Scholar, and ClinicalTrials.gov were systematically searched. Only studies comparing fractional CO₂ laser with needling-based monotherapy treating facial atrophic acne scars in adults were included. A random-effects model was employed for meta-analysis using Review Manager (RevMan) to compare efficacy and safety outcomes. A total of 17 studies were included in the meta-analysis. For primary efficacy outcomes, the results were non-significant for mean scar score reduction (SMD: -1.08, 95% CI: [-2.48, 0.32], I² = 97%) or mean quantitative scar reduction (SMD: 0.12, 95% CI: [-0.80, 1.04], I² = 92%), with significant heterogeneity. However, categorical treatment success was significantly high for CO₂ laser (RR: 1.10, 95% CI: [1.01, 1.20], I² = 0%). For safety outcomes, fractional CO₂ laser showed significantly high risk of post-inflammatory hyperpigmentation (PIH) as compared to standard microneedling (RR: 3.04, 95% CI: [1.49, 6.21], I² = 3%), but showed significantly low pain scores as compared to RF microneedling (SMD: -0.74, 95% CI: [-1.27, -0.21], I² = 0%). No significant differences were found for erythema, crusting/scabbing, or edema. Both fractional CO₂ laser and microneedling procedures show comparable efficacy in treating atrophic acne scars, however, patient variables such as skin type, scar type, and possible complications should be taken into consideration. Moreover, further tailored therapies are crucial to treating acne scars with low risk for complications.